TrialHaematologica2015

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.

Marina Konopleva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.